Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Dec 2024 value amounting to $94.8 million.

  • Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) rose 18.49% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 18.49%. This contributed to the annual value of $94.8 million for FY2024, which is 12.85% up from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) is $94.8 million, which was up 12.85% from $84.0 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $94.8 million during FY2024, and its lowest value of $55.4 million during FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $84.0 million (recorded in 2023), while the average stood at $82.3 million.
  • Data for Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY rose of 23.27% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $55.4 million in 2020, then grew by 14.18% to $63.2 million in 2021, then grew by 7.77% to $68.1 million in 2022, then increased by 23.27% to $84.0 million in 2023, then climbed by 12.85% to $94.8 million in 2024.